Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.

Esophagus · 2022 · PMC8739314 · PMID 34591237

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

In the current analysis from KEYNOTE-181 in Japanese patients, pembrolizumab demonstrated a positive trend for survival benefit in all patients (all but two patients had SCC) and for patients with CPS ≥ 10, with HRs for OS ranging from 0.67 to 0.70.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.